Protein biomarkers and drug design for cancer treatments

European Journal of Cancer Prevention

Volumn 13, Issue 4, 2004, Pages 297-305

  Hanke, J H ^a   Webster, K R ^a   Ronco, L V ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Biomarker; Drug discovery; Protein

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CA 125 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GREEN FLUORESCENT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAD; PROTEIN KINASE B; TAMOXIFEN; TRASTUZUMAB;

ADENOMATOUS POLYP; BREAST CARCINOMA; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CANCER THERAPY; CLINICAL TRIAL; COLON CARCINOMA; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; DRUG SYNTHESIS; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MAMMOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TUMOR BIOPSY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UTERINE CERVIX CARCINOMA IN SITU; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUGS, INVESTIGATIONAL; FEMALE; FORECASTING; HUMANS; MALE; NEOPLASMS; ONCOGENE PROTEINS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 4143092900     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cej.0000136569.63374.8e     Document Type: Review

References (89)

1. Adam B, Qu Y, Davis J, et al. (2003). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62: 3609-3614. [see comment in Cancer Res 2003 May 15; 63: 2701; author reply 2701-2).
2. Adam B, Qu Y, Davis J, et al. (2003). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62: 3609-3614. [see comment in Cancer Res 2003 May 15; 63: 2701; author reply 2701-2).
3. Albanell J, Rojo F, Averbuch S, et al. (2002). Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110-124.
4. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ (2001). ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 94: 774-782.
5. Baselga J, Rischin D, Ranson M, et al. (2002). Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302. [see comment in J Clin Oncol 2002 Nov 1; 20: 4276-8].
6. Baselga J, Rischin D, Ranson M, et al. (2002). Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302. [see comment in J Clin Oncol 2002 Nov 1; 20: 4276-8].
7. Bishop P, Myers T, Robey R, et al. (2002). Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 21: 119-127.
8. Borg A, Baldetorp B, Ferno M, et al. (1994). ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81: 137-144.
9. Bouvet M, Yang M, Nardin S, et al. (2000). Chronologically-specific metastatic targeting of human pancreatic tumors in orthotopic models. Clin Exp Metastasis 18: 213-218.
10. Brawer MK (1999). Prostate-specific antigen: current status. Cancer J Clin 49: 264-281.
11. Casciari JJ, Hollingshead MG, Alley MC, et al. (1994). Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model. J Natl Cancer Inst 86: 1846-1852.
12. Catalona WJ, Southwick PC, Slawin KM, et al. (2000). Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 56: 255-260.
13. Chaurand P, Stoeckli M, Caprioli RM (1999). Direct profiling of proteins in biological tissue sections by MALDI mass spectrometry. Anal Chem 71: 5263-5270.
14. Chin L, Tam A, Pomerantz J, et al. (1999). Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468-472.
15. Cobleigh MA, Vogel CL, Tripathy D, et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648.
16. Contag PR., Olomu IN, Stevenson DK, Contag CH (1998). Bioluminescent indicators in living mammals. Nature Med 4: 245-247.
17. Dykes D, Abbott B, Mayo J, et al. (1992). Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib Oncol 42: 1-22.
18. Elledge R, Green S, Ciocca D, et al. (1998). HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4: 7-12.
19. Espina V, Mehta A, Winters M, et al. (2003). Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 3: 2091-2100.
20. Fabian C, Kimler B, Brady D, et al. (2002). A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 8: 3105-3117.
21. Fidler IJ, Wilmanns C, Staroselsky A, et al. (1994). Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev 13: 209-222.
22. Fisher B, Dignam J, Wolmark N, et al. (1998). Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16: 441-452.
23. Formelli F (2000). Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial. J Cell Biochem 77: 73-79.
24. Gilmore AP, Valentijn AJ, Wang P, et al. (2002). Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 277: 27643-27650.
25. Grubb R, Calvert V, Wulkuhle J, et al. (2003). Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 3: 2142-2146.
26. Grunwald V, Hidalgo M (2003). Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95: 851-867.
27. Haab BB (2001). Advances in protein microarray technology for protein expression and interaction profiling. Curr Opin Drug Discovery Dev 4: 116-123.
28. Haab BB, Dunham MJ, Brown PO (2001). Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol 2: RESEARCH0004.
29. Harper ME, Goddard L, Glynne-Jones E, et al. (2002). Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor. Prostate 52: 59-68.
30. Hoffman RM (1998). Orthotopic transplant mouse models with green fluorescent protein-expressing cancer cells to visualize metastasis and angiogenesis. Cancer Metastasis Rev 17: 271-277.
31. Hoffman RM (1999). Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17: 343-359.
32. Hoffman RM (2002). In vivo imaging of metastatic cancer with fluorescent proteins. Cell Death Differ 9: 786-789.
33. Hollingshead MG, Alley MC, Camalier RF (1995). In vivo cultivation of tumor cells in hollow fibers. Life Sci 57: 131-141.
34. Jost M, Kari C, Rodeck UI (2000). The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 10: 505-510.
35. Kallioniemi OP, Wagner U, Kononen J, Sauter G (2001). Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10: 657-662.
36. Kim WH (2001). Tissue array technology for translational research. From gene discovery to application. Exp Mol Med 33: 135-148.
37. Kim WH, Rubin MA, Dunn RL (2002). High-density tissue microarray. Am J Surg Pathol 26: 1236-1238; Discussion 1238.
38. Kononen J, Bubendorf L, Kaliioniemi A, et al. (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med 4: 844-847.
39. Kuo TH, Kubota T, Watanabe M, et al. (1993). Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of Orthotopic models to obtain relevant drug evaluation data. Anticancer Res 13: 627-630.
40. Lilley KS, Razzaq A, Dupree P (2002). Two-dimensional gel electrophoresis: recent advances in sample preparation, detection and quantitation. Curr Opin Chem Biol 6: 46-50.
41. Liotta LA, Espina V, Mehta AI, et al. (2003). Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3: 317-325.
42. Magne N, Fischel J, Dubreuil A, et al. (2002). Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ('Iressa'). Br J Cancer 86: 1518-1523.
43. Mann G, Fowler K, Gabriel A, et al. (1993). Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 73: 249-261.
44. Margolese RG, Fisher B, Hortobagyi GN, Bloomer WD (2000). Neoplasms of the breast. In: Robert DWK, Bast C, Pollock RE, Weichselbaum RR, Holland JF, Frei E (editors): Cancer Medicine, BC Decker: Hamilton, pp. 1735-1822.
45. Modugno F, Ovarian C and High-Risk Women Symposium P (2003). Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. Gynecol Oncol 91: 15-31.
46. Mousses S, Bubendorf L, Wagner U, et al. (2002a). Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res 62: 1256-1260.
47. Mousses S, Kallioniemi A, Kauraniemi P, Elkahloun A, Kallioniemi OP (2002b). Clinical and functional target validation using tissue and cell microarrays. Curr Opin Chem Biol 6: 97-101.
48. Muller AD, Sonnenberg A (1995). Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 123: 904-910.
49. Muss H, Thor A, Berry D et al. (1994). c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266. [see comment in N Engl J Med 1994; 330: 1308-9] [erratum N Engl J Med 1994; 331: 211].
50. Muss H, Thor A, Berry D et al. (1994). c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266. [see comment in N Engl J Med 1994; 330: 1308-9] [erratum N Engl J Med 1994; 331: 211].
51. Nakajima M, Morikawa K, Fabra A, Bucana CD, Fidler IJ (1990). Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells [see comment]. J Natl Cancer Inst 82: 1890-1898.
52. Nishizuka S, Chen ST, Gwadry FG, et al. (2003). Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 63: 5243-5250.
53. Normanno N, Campiglio M, De LA (2002). Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13: 65-72.
54. O'Leary TJ (2001). Standardization in immunohistochemistry. Appl Immunohistochem Mol Morphol 9: 3-8.
55. O'Shaughnessy J, Kelloff G, Gordon G, et al. (2002). Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8: 314-346. [see comment in Clin Cancer Res 2002; 8: 305-13].
56. O'Shaughnessy J, Kelloff G, Gordon G, et al. (2002). Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8: 314-346. [see comment in Clin Cancer Res 2002; 8: 305-13].
57. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G (1999). Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3: 565-577.
58. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA (2002a). Clinical proteomics: translating benchside promise into bedside reality. Nature Rev Drug Discov 1: 683-695.
59. Petricoin ER, Ornstein D, Paweletz C, et al. (2002b). Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94: 1576-1578. [see comment in J Natl Cancer Inst 2003; 95: 489-90; author reply 490-1].
60. Petricoin ER, Ornstein D, Paweletz C, et al. (2002b). Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94: 1576-1578. [see comment in J Natl Cancer Inst 2003; 95: 489-90; author reply 490-1].
61. Peus D, Hamacher L, Pittelkow M (1997). EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 109: 751-756.
62. Plowman J, Dykes D, Hollingshead M, Simpson-Herren L, Alley M (1997). Human tumor xenograft models. In: Teicher B (editor): Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Totowa, NJ: Humana Press, pp. 101-125.
63. Qu Y, Adam B, Yasui Y, et al. (2002). Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 48: 1835-1843.
64. Rashidi B, Yang M, Jiang P, et al. (2000). A highly metastatic Lewis lung carcinoma orthotopic green fluorescent protein model. Clin Exp Metastasis 18: 57-60.
65. Rehemtulla A, Stegman LD, Cardozo SJ, et al. (2000). Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia (New York) 2: 491-495.
66. Reyzer ML, Hsieh Y, Ng K, Korfmacher WA, Caprioli RM (2003). Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom 38: 1081-1092.
67. Schairer C, Hill D, Sturgeon S, et al. (2004). Serum concentrations of IGF-1, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 108: 773-779.
68. Schweitzer B, Kingsmore SF (2002). Measuring proteins on microarrays. Curr Opin Biotechnol 13: 14-19.
69. Sewell JM, Macleod KG, Ritchie A, Smyth JF, Langdon SP (2002). Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ('Iressa'). Br J Cancer 86: 456-462.
70. Sheiner LB, Steimer JL (2000). Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40: 67-95.
71. Slamon D, Clark G, Wong S, et al. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
72. Slaughter D, Southwick H, Smejkal W (1953). 'Field cancerization' in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer (Philadelphia) 6: 963-968.
73. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM (2001). Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nature Med 7: 493-496.
74. Sullivan Pepe M, Etzioni R, Feng Z, et al. (2001). Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93: 1054-1061.
75. Sweeney TJ, Mailander V, Tucker AA, et al. (1999). Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA 96: 12044-12049.
76. Van Dyke T, Jacks T (2002). Cancer modeling in the modern era: progress and challenges. Cell 108: 135-144.
77. Wakeling AE, Guy SP, Woodburn JR, et al. (2002). ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754.
78. Whitehouse C, Solomon E (2003). Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol 88: S152-S157.
79. Wilmanns C, Fan D, O'Brian CA, et al. (1992). Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 52: 98-104.
80. Wilson DS, Nock S (2002). Functional protein microarrays. Curr Opin Chem Biol 6: 81-85.
81. Winawer SJ, Zauber AG, Ho MN, et al. (1993). Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329: 1977-1981.
82. Workman P (2002), Challenges of PK/PD measurements in modern drug development. Eur J Cancer 38: 2189-2193.
83. Wulfkuhle JD, McLean KC, Paweletz CP, et al. (2001). New approaches to proteomic analysis of breast cancer. Proteomics 1: 1205-1215.
84. Wulfkuhle J, Aquino J, Calvert V, et al. (2003). Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3: 2085-2090.
85. Yang M, Baranov E, Jiang P, et al. (2000). Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci USA 97: 1206-1211.
86. Yang M, Jiang P, Sun FX, et al. (1999). A fluorescent Orthotopic bone metastasis model of human prostate cancer. Cancer Res 59: 781-786.
87. Yu Y, Annala AJ, Barrio JR, et al. (2000). Quantification of target gene expression by imaging reporter gene expression in living animals. Nature Med 6: 933-937.
88. Zhen Y, Caprioli RM, Staros JV (2003). Characterization of glycosylation sites of the epidermal growth factor receptor. Biochemistry 42: 5478-5492.
89. Zhu W, Wang X, Ma Y, et al. (2003). Detection of cancer-specific markers amid massive mass spectral data. Proc Natl Acad Sci USA 100: 14666-14671.